Phase II Clinical Trial of Mifepristone an Eye Drop Treatment for Steroid Associated Elevated Intraocular Pressure
Global bio-nanotech company pSivida Limited (NASDAQ:PSDV) (ASX:PSD) (Xetra:PSI) today announced the initiation of a Phase II clinical trial of Mifepristone (otherwise known as RU486) as an eye drop treatment for steroid associated elevated intraocular pressure (IOP).
The investigator-sponsored trial will involve up to 45 patients in the United States. pSivida will be supplying clinical trial material for this study and has filed a patent application on this product class.
Elevated IOP may occur in patients receiving steroidal treatment for chronic eye diseases. The trial will investigate the use of Mifepristone as a means to prevent elevation of IOP from intraocular steroid exposure. Mifepristone is a steroid receptor antagonist ("steroid blocker") already approved by the FDA. This study represents a potential new use of an existing drug, made possible by a new delivery system.